COLLEGEVILLE, Pa.--(BUSINESS WIRE)--Synergy Biomedical, LLC, a developer of novel biomaterial products, announced today that it was issued its first key patent (U.S. Patent 8,506,981) covering the use of optimized bioactive glass spheres for bone repair.
“The recently issued patent demonstrates Synergy’s commitment to developing next generation bone graft products,” stated Mark Borden, Ph.D., president and CEO of Synergy. “We have identified an optimal particle shape and size that improves the inherent ability of bioactive glass to heal bone. Our plan is to expand our product portfolio by incorporating this novel technology into a variety of products that will offer enhanced bone formation and healing.”
Synergy’s first product, BIOSPHERE PUTTY, utilizes the patented bioactive glass spheres and was recently launched in July of 2013. The product provides surgeons with a moldable bone graft material that has the highest bioactive glass content on the market.
About Synergy Biomedical, LLC
Founded in 2011, Synergy Biomedical is a privately-held medical device company focused on bringing innovative biomaterial based products to the orthopaedic and spinal markets. The Company’s BioSphere® Technology represents a unique approach to advancing bone graft technology, and improving bone healing and patient outcomes.
